Calliditas Therapeutics AB announced positive topline results from the global, randomized, double-blind, placebo-controlled Phase 3 clinical trial NefIgArd, which investigated the effect of Nefecon delayed release capsules) versus placebo in patients with primary IgA nephropathy.
